Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy

NCT02474914 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Periampullary Carcinoma Resectable

Interventions

DRUG: Octreotide
DRUG: Placebo

Sponsor

Mansoura University